Status:
COMPLETED
Study Evaluating Estradiol/Trimegestone in Vasomotor Symptoms (VMS) in Post-Menopausal Women.
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Postmenopause
Eligibility:
FEMALE
45-55 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate vasomotor symptoms (VMS) control of the continuous regimen 17 b estradiol/trimegestone combination.
Eligibility Criteria
Inclusion
- Generally healthy postmenopausal women 45 to 55 years of age inclusive, with at least 1 year of natural occurring amenorrhea, with vasomotor symptoms, with at least 4 hot flushes per day
- Intact uterus
Exclusion
- Known or suspected breast carcinoma or estrogen-dependent neoplasm
- Undiagnosed abnormal genital bleeding
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2007
Estimated Enrollment :
133 Patients enrolled
Trial Details
Trial ID
NCT00195455
Start Date
February 1 2005
End Date
March 1 2007
Last Update
December 20 2007
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Guadalajara, Jalisco, Mexico, 44340
2
Monterrey, N.L., Mexico, 64000
3
Monterrey, N.L., Mexico, 64460
4
Mexico City, Mexico, 01030